Related Experiment Videos
[Protection against influenza by genetically engineered vaccines]
1Department of Industrial Chemistry, Chiba Institute of Technology/High Technology Research Center.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 28, 2001
Summary
Genetically engineered vaccines offer a novel immunotherapy approach, inducing potent antigen-specific immune responses. These DNA vaccines show promise in overcoming unresponsiveness and enhancing both cellular and humoral immunity against viral antigens.
Area of Science:
- Immunology
- Vaccinology
- Genetic Engineering
Context:
- Viral vector recombinant DNA vaccines represent a novel vaccination strategy.
- This approach introduces genetic material directly into cells to elicit an immune response.
- It signifies a new frontier in immunotherapy for infectious diseases.
Purpose:
- To explore the potential of genetically engineered vaccines in inducing antigen-specific immune responses.
- To evaluate their efficacy in generating both humoral and cellular immunity.
- To assess their ability to overcome unresponsiveness associated with traditional vaccines.
Summary:
- Genetically engineered vaccines are administered to induce antigen-specific immune responses.
- Studies show DNA vaccines encoding influenza hemagglutinin (HA) induce humoral immunity.
- Conversely, influenza virus nucleoprotein (NP) DNA vaccines stimulate Th-1 type cellular immunity, including cytotoxic T lymphocytes (CTL).
Impact:
- These advanced vaccines may offer more potent immune responses than conventional vaccines.
- They hold promise for inducing robust cellular immune responses crucial for combating viral infections.
- Genetically engineered vaccines could provide a solution for individuals unresponsive to existing vaccine platforms.